KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharmaceuticals is set to thrive in the pharmaceutical industry, driven by its innovative research in the kallikrein-kinin system, particularly with its FDA-approved oral therapy, EKTERLY. Recently, the company announced its acquisition by Chiesi Group in a cash transaction valued at $1.9 billion, showing the confidence and valuation of the company. In addition, the strong adoption and Rx refills for EKTERLY highlight the satisfaction of patients and prescribers, positioning the company for further growth and expansion in the competitive HAE therapy market. However, there is a potential commercialization risk given the market's competitiveness, but with KALV's track record and unique offerings, it is well-positioned to overcome this challenge and excel in the long term.

KalVista Pharmaceuticals is set for a near-term value realization with its acquisition by Chiesi Group for a meaningful premium to recent trading levels. The transaction is expected to close in 3Q26, subject to customary conditions, and key risks to deal completion include shareholder tender thresholds, competing acquisition proposals, and transaction timing or closing delays. With a significant increase in operating expenses and the need for additional capital, there is a risk of significant financing challenges for KALV in the future, despite its launched product and potential for sales growth.